Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Jason Flamm, Peter Ruane et al.|The Lancet HIV|2021Cited by 91
Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of TreatmentXinyan Zhang, Ronald J. Bosch, Peter W. Hunt et al.|HIV Clinical Trials|2013Cited by 20
Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral TherapySara E. Looby, Markella V. Zanni, Michelle Cespedes et al.|Clinical Infectious Diseases|2022Cited by 12
Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)Gerald S. Bloomfield, Pamela S. Douglas, Maya Watanabe et al.|Circulation Heart Failure|2025Cited by 2
Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of TreatmentRonald J. Bosch, Michelle Cespedes, Scott M. Hammer et al.|UNC Libraries|2020Cited by 1